Bionor is a biopharmaceutical company with first mover potential to advance a possible functional HIV cure

Latest news

Hide mandatory notifications of trade

Vacc-C5 phase I/II clinical study published in BMC infectious diseases

Scientific .2017

The Vacc-C5 clinical trial is included as part of the doctor thesis of Kristin Brekke at Oslo University Hospital

Bionor Pharma presents REDUC clinical trial results as a poster at GLOBVAC

Scientific .2017

The Research Council of Norway's 10th Conference on Global Health and Vaccination Research where Bionor presents the Vacc-4x REDUC clinical trial results.

Bionor's CSO Maja Sommerfelt was honorable speaker at Vaccines 2017

Scientific .2017

CSO Maja Sommerfelt was invited as an honorable speaker at Vaccines 2017 in Baltimore, USA, where she presented data from the REDUC clinical trial and chaired the session "HIV/AIDS Vaccines & Clinical Trials, Human Vaccines – Infectious & Non Infectious Diseases & Immunology/Animal models"

Vacc-C5 phase I/II clinical study published in BMC infectious diseases

Scientific .2017

The Vacc-C5 clinical trial is included as part of the doctor thesis of Kristin Brekke at Oslo University Hospital

Bionor Pharma presents REDUC clinical trial results as a poster at GLOBVAC

Scientific .2017

The Research Council of Norway's 10th Conference on Global Health and Vaccination Research where Bionor presents the Vacc-4x REDUC clinical trial results.

Bionor's CSO Maja Sommerfelt was honorable speaker at Vaccines 2017

Scientific .2017

CSO Maja Sommerfelt was invited as an honorable speaker at Vaccines 2017 in Baltimore, USA, where she presented data from the REDUC clinical trial and chaired the session "HIV/AIDS Vaccines & Clinical Trials, Human Vaccines – Infectious & Non Infectious Diseases & Immunology/Animal models"

Go to news section

Featured content